Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Promising therapies for the treatment of myasthenia gravis.
Uysal SP, Morren JA. Uysal SP, et al. Among authors: morren ja. Expert Opin Pharmacother. 2024 Mar;25(4):395-408. doi: 10.1080/14656566.2024.2332610. Epub 2024 Mar 25. Expert Opin Pharmacother. 2024. PMID: 38523508 Review.
Myasthenia gravis: Frequently asked questions.
Morren JA, Li Y. Morren JA, et al. Cleve Clin J Med. 2023 Feb 1;90(2):103-113. doi: 10.3949/ccjm.90a.22017. Cleve Clin J Med. 2023. PMID: 36724914 Free article. Review.
Time to Diagnosis and Factors Affecting Diagnostic Delay in Amyotrophic Lateral Sclerosis.
Richards D, Morren JA, Pioro EP. Richards D, et al. Among authors: morren ja. In: Araki T, editor. Amyotrophic Lateral Sclerosis [Internet]. Brisbane (AU): Exon Publications; 2021 Jul 25. Chapter 2. In: Araki T, editor. Amyotrophic Lateral Sclerosis [Internet]. Brisbane (AU): Exon Publications; 2021 Jul 25. Chapter 2. PMID: 34473440 Free Books & Documents. Review.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
20 results